A Phase II open-label multicenter exploratory study to assess efficacy of Pembrolizumab re-challange as second or further line in patients with advanced non - small cell lung cancer

Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2018
This article has no abstract
Epistemonikos ID: b16e79fc76f5309a239f0efe22d32450d1cc1ec6
First added on: Jan 23, 2025